1. Home
  2. BLCO vs FSK Comparison

BLCO vs FSK Comparison

Compare BLCO & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLCO
  • FSK
  • Stock Information
  • Founded
  • BLCO 1853
  • FSK 2007
  • Country
  • BLCO Canada
  • FSK United States
  • Employees
  • BLCO N/A
  • FSK N/A
  • Industry
  • BLCO Ophthalmic Goods
  • FSK Investment Managers
  • Sector
  • BLCO Health Care
  • FSK Finance
  • Exchange
  • BLCO Nasdaq
  • FSK Nasdaq
  • Market Cap
  • BLCO 7.0B
  • FSK 6.0B
  • IPO Year
  • BLCO 2022
  • FSK N/A
  • Fundamental
  • Price
  • BLCO $18.02
  • FSK $21.30
  • Analyst Decision
  • BLCO Buy
  • FSK Hold
  • Analyst Count
  • BLCO 12
  • FSK 9
  • Target Price
  • BLCO $20.91
  • FSK $20.00
  • AVG Volume (30 Days)
  • BLCO 524.8K
  • FSK 1.6M
  • Earning Date
  • BLCO 10-30-2024
  • FSK 11-06-2024
  • Dividend Yield
  • BLCO N/A
  • FSK 13.15%
  • EPS Growth
  • BLCO N/A
  • FSK N/A
  • EPS
  • BLCO N/A
  • FSK 1.89
  • Revenue
  • BLCO $4,684,000,000.00
  • FSK $1,761,000,000.00
  • Revenue This Year
  • BLCO $17.39
  • FSK N/A
  • Revenue Next Year
  • BLCO $6.18
  • FSK N/A
  • P/E Ratio
  • BLCO N/A
  • FSK $11.29
  • Revenue Growth
  • BLCO 18.01
  • FSK N/A
  • 52 Week Low
  • BLCO $13.16
  • FSK $18.31
  • 52 Week High
  • BLCO $21.69
  • FSK $22.39
  • Technical
  • Relative Strength Index (RSI)
  • BLCO 36.81
  • FSK 49.67
  • Support Level
  • BLCO $17.71
  • FSK $20.94
  • Resistance Level
  • BLCO $18.99
  • FSK $21.49
  • Average True Range (ATR)
  • BLCO 0.52
  • FSK 0.28
  • MACD
  • BLCO -0.17
  • FSK -0.08
  • Stochastic Oscillator
  • BLCO 10.17
  • FSK 30.51

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is a business development company based in the United States. Its portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. It is focused on providing customized credit solutions to private upper middle-market companies, which it generally defines as companies with annual EBITDA of at least $50 million at the time of investment.

Share on Social Networks: